DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Information source: FORUM Pharmaceuticals Inc
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia; Impaired Cognition

Intervention: EVP-6124 (Drug); Placebo (Drug)

Phase: Phase 3

Status: Active, not recruiting

Sponsored by: FORUM Pharmaceuticals Inc


The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.

Clinical Details

Official title: A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Change from Baseline in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) to Day 182

Change from Baseline in the Schizophrenia Cognition Rating Scale (SCoRs) to Day 182

Safety and Tolerability of EVP-6124 or Placebo in Subjects with Schizophrenia

Secondary outcome:

Change from Baseline in the Positive and Negative Symptom Scale (PANSS) to Day 182

Change from Baseline in the Clinical Global Impression-Severity (CGI-S) to Day 182

Change from Baseline in the Clinical Global Impression Change Scale (CGI-C) to Day 182

Change from Baseline in the EuroQOL-5D (EQ-5D) to Day 182


Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Both.


Inclusion Criteria:

- Age 18 to 50 years of age, inclusive

- Signed informed consent, indicating that the subject understands the purpose of and

procedures required for the study, before the initiation of any study specific procedures. Subjects who are unable to provide informed consent will not be included in the study.

- Resides in a stable living situation, according to the investigator's judgment, and

must have an identified informant who should be consistent throughout the study. If possible, the informant should accompany the subject or be available for in person ratings at the screening, baseline (Day 1), and final study visits. In person informant ratings on all relevant study visits are preferred whenever possible. However, if the informant is not available for in person ratings, telephone interview is acceptable. The informant must be available for a telephone interview throughout the study at all visits. As long as both the informant visit and subject visit are within the study visit windows, it is not necessary that they occur on the same day. The informant must interact with the subject at least 2 times a week.

- Diagnosis of Schizophrenia of at least 3 years duration. This diagnosis can be

established utilizing the SCID-I, direct clinical assessments, family, informants, and confirmation of diagnosis from clinical sources. These may include medical records, confirmation of diagnosis by treating clinician through telephone contact, or written confirmation from treating clinic. If the listed sources are not available, other sources of diagnostic confirmation may also be acceptable after discussion with the medical monitor.

- Treated with atypical antipsychotic drug (in any approved dosage form) other than

Clozapine at a stable dose for at least 8 weeks prior to screening and be clinically stable; the subject must remain clinically stable (in the opinion of the principal investigator) through randomization. The use of up to 2 atypical antipsychotic drugs is permitted, as long as in the opinion of the investigator, the second medication is not required to control treatment-resistant or intractable psychotic symptoms. No subject will be washed off antipsychotic therapy to become eligible for this study.

- Schizophrenia clinical symptom burden severity defined by the following: a Brief

Psychiatric Rating Scale (BPRS) Conceptual Disorganization item score ≤ 4; and a BPRS Hallucinatory Behavior item score ≤ 5, or an Unusual Thought Content item score ≤ 5. Either Hallucinatory Behavior or Unusual Thought Content, but not both, may have a score of 6 (but not > 6).

- Simpson-Angus Scale (SAS) total score ≤ 6

- Calgary Depression Scale for Schizophrenia (CDSS) total score ≤ 10

- General health status acceptable for participation in a 26-week clinical study

- Fertile, sexually active subjects (men and women) must use an effective method of

contraception during the study

- Fluency (oral and written) in the language in which the standardized tests will be


- The ability to refrain from using any tobacco or other nicotine-containing products

for at least 30 minutes before any cognitive testing Exclusion Criteria:

- Hospitalization within 12 weeks before screening or during the screening period, or

change of antipsychotic medication or dose within 8 weeks before screening or during the screening period.

- Participation in another therapeutic (medication administration) clinical study

within the past 2 months.

- Psychiatric hospitalization or incarcerations due to breakthrough symptoms or acute

exacerbations for a period of 3 months before screening. Subjects with a recent "social" hospitalization or incarceration may be entered into screening after consultation with the medical monitor

- Likelihood, in the opinion of the investigator, that either the subject or informant

will be unable to complete a 26-week study

- Treatment with prohibited antipsychotic drug, and/or treatment with more than 2

permitted antipsychotic drugs. Treatment with a first-generation antipsychotic drug (typical antipsychotic) is prohibited unless it is administered at a low dose after discussion with the medical monitor

- Current treatment with any anticholinergic agent

- Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV)

criteria met for alcohol abuse within the past 3 months or substance abuse (other than nicotine) within the last 6 months before screening

- Significant suicide risk as defined by 1) suicidal ideation as endorsed on items 4 or

5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within the past year; 2) suicidal behavior detected by the C-SSRS during the past 2 years, or 3) psychiatric interview and examination

- Stroke within 6 months before screening, history of brain tumor, subdural hematoma,

or other clinically significant neurological condition, head trauma with loss of consciousness within 12 months before screening

- Monoamine oxidase inhibitor antidepressants or tricyclic medications used in

antidepressant doses are excluded. Other antidepressant medications are allowed if the subject has been treated with a stable dose for at least 3 months before screening

- Immunosuppressants, mood stabilizers, chronic use of a sedative hypnotic drug,

chronic intake of clinically significant doses of opioid containing analgesics or any current methadone treatment all in the judgment of the investigator may be permitted depending on the circumstance

- Use of Central Nervous System(CNS) stimulants

- Nicotine therapy (including patches), varenicline (Chantix), or similar therapeutic

agent within the last six months before screening

- Use of a benzodiazepine medication is allowed if the subject has not had a change in

medication or dose for at least 3 months. For subjects prescribed benzodiazepines, short-acting benzodiazepines are to be used whenever possible. Use of longer-acting benzodiazepines may be acceptable if prior authorization is obtained from the medical monitor. When possible, benzodiazepines should not be administered within 3 hours before cognitive testing. The use of more than one sedative-hypnotic medication is not allowed.

Locations and Contacts

Caba, Argentina

Cordoba, Argentina

Mendoza, Argentina

Melbourne, Australia

Rio de Janeiro, Brazil

Sao Paulo, Brazil

Achim, Germany

Berlin, Germany

Dusseldorf, Germany

Freiburg, Germany

Leipzig, Germany

Mittweida, Germany

Munchen, Germany

Regebsburg, Germany

Regensburg, Germany

Stralsund, Germany

Wiesbaden, Germany

Bialystok, Poland

Gdansk, Poland

Lodz, Poland

Lublin, Poland

Torun, Poland

Tuszyn, Poland

Warszawa, Poland

Moscow, Russian Federation

Saint-Petersburg, Russian Federation

Stavropol, Russian Federation

Belgrade, Serbia

Kragujevac, Serbia

Nis, Serbia

Novi Knezevac, Serbia

Singapore, Singapore

Barcelona, Spain

Madrid, Spain

Donetsk, Ukraine

Ivano-Frankivsk, Ukraine

Kharkiv, Ukraine

Kyiv, Ukraine

Lugansk, Ukraine

Calgary, Alberta, Canada

Tucson, Arizona, United States

Talagi, Arkangelsk region, Russian Federation

Mataro, Barcelona, Spain

Penticton, British Columbia, Canada

La Plata, Buenos Aires, Argentina

Anaheim, California, United States

Bellflower, California, United States

Costa Mesa, California, United States

Culver City, California, United States

Downey, California, United States

Escondido, California, United States

Los Angeles, California, United States

Oceanside, California, United States

Orange, California, United States

San Diego, California, United States

Torrance, California, United States

Salamanca, Castilla y Leon, Spain

Zamora, Castilla y Leon, Spain

Mexico, D.F, Mexico

Lauderhill, Florida, United States

Miami, Florida, United States

North Miami, Florida, United States

Orange City, Florida, United States

Atlanta, Georgia, United States

Chicago, Illinois, United States

Guadalajara, Jalisco, Mexico

Wichita, Kansas, United States

Shreveport, Louisiana, United States

Alcorcon, Madrid, Spain

Coslada, Madrid, Spain

Minneapolis, Minnesota, United States

Flowood, Mississippi, United States

Creve Coeur, Missouri, United States

O'Fallon, Missouri, United States

St. Louis, Missouri, United States

Omaha, Nebraska, United States

Monterrey, Neuvo Leon, Mexico

Marlton, New Jersey, United States

Albuquerque, New Mexico, United States

Cedarhurst, New York, United States

New York, New York, United States

Charlotte, North Carolina, United States

Durham, North Carolina, United States

Cleveland, Ohio, United States

Oklahoma City, Oklahoma, United States

Chatham, Ontario, Canada

Kingston, Ontario, Canada

Conshohocken, Pennsylvania, United States

Norristown, Pennsylvania, United States

Philadelphia, Pennsylvania, United States

Vigo, Pontevedra, Spain

Montreal, Quebec, Canada

Itapira, SP, Brazil

Dallas, Texas, United States

Additional Information

Starting date: October 2012
Last updated: June 23, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017